Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The design of compounds with desirable properties–The anti-HIV case study (CROSBI ID 323324)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Novak, Jurica ; Pathak, Prateek ; Grishina, Maria A. ; Potemkin, Vladimir A. The design of compounds with desirable properties–The anti-HIV case study // Journal of computational chemistry, 44 (2023), 10; 1016-1030. doi: 10.1002/jcc.27061

Podaci o odgovornosti

Novak, Jurica ; Pathak, Prateek ; Grishina, Maria A. ; Potemkin, Vladimir A.

hrvatski

The design of compounds with desirable properties–The anti-HIV case study

Efficacy and safety are among the most desirable characteristics of an ideal drug. The tremendous increase in computing power and the entry of artificial intelligence into the field of computational drug design are accelerating the process of identifying, developing, and optimizing potential drugs. Here, we present novel approach to design new molecules with desired properties. We combined various neural networks and linear regression algorithms to build models for cytotoxicity and anti-HIV activity based on Continual Molecular Interior analysis (CoMIn) and Cinderella's Shoe (CiS) derived molecular descriptors. After validating the reliability of the models, a genetic algorithm was coupled with the Des-Pot Grid algorithm to generate new molecules from a predefined pool of molecular fragments and predict their bioactivity and cytotoxicity. This combination led to the proposal of 16 hit molecules with high anti-HIV activity and low cytotoxicity. The anti-SARS-CoV-2 activity of the hits was predicted.

3CLpro ; cytotoxicity ; drug repurposing ; HIV-1 protease ; QSAR

nije evidentirano

engleski

The design of compounds with desirable properties – The anti‐HIV case study

nije evidentirano

3CLpro ; cytotoxicity ; drug repurposing ; HIV-1 protease ; QSAR

nije evidentirano

Podaci o izdanju

44 (10)

2023.

1016-1030

objavljeno

0192-8651

10.1002/jcc.27061

Povezanost rada

Interdisciplinarne prirodne znanosti, Kemija

Poveznice
Indeksiranost